Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Emergency Medicine
Volume 2017, Article ID 5045087, 7 pages
https://doi.org/10.1155/2017/5045087
Case Report

Treatment of Community-Acquired Pneumonia: A Case Report and Current Treatment Dilemmas

No Resistance Consulting Group, Mountain Brook, AL, USA

Correspondence should be addressed to Glenn Harnett; moc.ecnatsiser-on@ttenrah.nnelg

Received 16 December 2016; Accepted 13 April 2017; Published 15 June 2017

Academic Editor: Ching H. Loh

Copyright © 2017 Glenn Harnett. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. M. File Jr. and T. J. Marrie, “Burden of community-acquired pneumonia in North American adults,” Postgraduate Medicine, vol. 122, no. 2, pp. 130–141, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. L. A. Mandell, “Epidemiology and etiology of community-acquired pneumonia,” Infectious Disease Clinics of North America, vol. 18, no. 4, pp. 761–776, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Xu, S. L. Murphy, K. D. Kochanek, and B. A. Bastian, “Deaths: final data for 2013,” National Vital Statistics Reports, vol. 64, no. 2, pp. 1–119, 2016. View at Google Scholar
  4. L. A. Mandell, R. G. Wunderink, A. Anzueto et al., “Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults,” Clinical Infectious Diseases, vol. 44, supplement 2, pp. S27–S72, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. G. S. Tillotson, “Where in the world? The role of geography in antibiotic resistance and the potential impact in pulmonary infections,” Postgraduate Medicine, vol. 128, no. 5, pp. 449-450, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Heath, National Disease and Therapeutic Index, IMS Health, 2014.
  7. N. Kamangar, “Bacterial pneumonia clinical presentation,” Medscape: Drugs & Diseases, 2016, http://emedicine.medscape.com/article/-clinical. View at Google Scholar
  8. M. L. Metersky, R. G. Masterton, H. Lode, T. M. File, and T. Babinchak, “Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza,” International Journal of Infectious Diseases, vol. 16, no. 5, pp. e321–e331, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Broulette, H. Yu, B. Pyenson, K. Iwasaki, and R. Sato, “The incidence rate and economic burden of community-acquired pneumonia in a working-age population,” American Health and Drug Benefits, vol. 6, no. 8, pp. 494–503, 2013. View at Google Scholar · View at Scopus
  10. R. Sato, G. G. Rey, S. Nelson, and B. Pinsky, “Community-acquired pneumonia episode costs by age and risk in commercially insured US adults aged ≥50 years,” Applied Health Economics and Health Policy, vol. 11, no. 3, pp. 251–258, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. M. S. Niederman, J. S. McCombs, A. N. Unger, A. Kumar, and R. Popovian, “The cost of treating community-acquired pneumonia,” Clinical Therapeutics, vol. 20, no. 4, pp. 820–837, 1998. View at Publisher · View at Google Scholar · View at Scopus
  12. C. M. Coley, Y.-H. Li, A. R. Medsger et al., “Preferences for home vs hospital care among low-risk patients with community-acquired pneumonia,” Archives of Internal Medicine, vol. 156, no. 14, pp. 1565–1571, 1996. View at Publisher · View at Google Scholar · View at Scopus
  13. W. S. Lim, M. M. van der Eerden, R. Laing et al., “Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study,” Thorax, vol. 58, no. 5, pp. 377–382, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Kenneth, M. A. Kochanek, L. Sherry, B. S. Murphy, M. D. Jiaquan Xu, and M. S. Betzaida Tejada-Vera, “Deaths: final data for 2014,” National Vital Statistics Reports, vol. 65, no. 4, pp. 1–122, 2016. View at Google Scholar
  15. D. M. Morens, J. K. Taubenberger, and A. S. Fauci, “Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness,” The Journal of Infectious Diseases, vol. 198, no. 7, pp. 962–970, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. J. M. Blondeau and N. Theriault, “Application of the formula for rational antimicrobial therapy (FRAT) to community-acquired pneumonia,” Journal of Infectious Diseases & Therapy, vol. 5, no. 1, p. 313, 2017. View at Publisher · View at Google Scholar
  17. C. Joseph, Y. Togawa, and N. Shindo, “Bacterial and viral infections associated with influenza,” Influenza and other Respiratory Viruses, vol. 7, supplement 2, pp. 105–113, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Asadi, D. T. Eurich, J.-M. Gamble, J. K. Minhas-Sandhu, T. J. Marrie, and S. R. Majumdar, “Guideline adherence and macrolides reduced mortality in outpatients with pneumonia,” Respiratory Medicine, vol. 106, no. 3, pp. 451–458, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Feldman and R. Anderson, “Antibiotic resistance of pathogens causing community-acquired pneumonia,” Seminars in Respiratory and Critical Care Medicine, vol. 33, no. 3, pp. 232–243, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. V. L. Yu, C. C. C. Chiou, C. Feldman et al., “An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome,” Clinical Infectious Diseases, vol. 37, no. 2, pp. 230–237, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. W. S. Lim, S. V. Baudouin, R. C. George et al., “British Thoracic Society guidelines for the management of community acquired pneumonia in adults: update 2009,” Thorax, vol. 64, supplement 3, pp. iii1–iii55, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. A. N. Makam, A. D. Auerbach, and M. A. Steinman, “Blood culture use in the emergency department in patients hospitalized for community-acquired pneumonia,” JAMA Internal Medicine, vol. 174, no. 5, pp. 803–806, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. H. I. R. Luna and G. Pankey, “The utility of blood culture in patients with community-acquired pneumonia,” The Ochsner Journal, vol. 3, no. 2, pp. 85–93, 2001. View at Google Scholar · View at Scopus
  24. C. Asche, C. McAdam-Marx, B. Seal, B. Crookston, and C. D. Mullins, “Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance,” Journal of Antimicrobial Chemotherapy, vol. 61, no. 5, pp. 1162–1168, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. R. K. Flamm, “Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program,” in Proceedings of the ICAAC, San Diego, Claif, USA, 2015.
  26. CDC Report, “Antibiotic resistance threats in the United States,” 2013.
  27. Center for Disease Dynamics EaPC, “Macrolide-resistant Streptococcus pneumoniae,” 2009.
  28. L. A. Mandell, “Something new for community-acquired pneumonia?” Clinical Infectious Diseases, vol. 63, no. 12, pp. 1681-1682, 2016. View at Publisher · View at Google Scholar
  29. P. B. Iannini, J. A. Paladino, B. Lavin, M. E. Singer, and J. J. Schentag, “A case series of macrolide treatment failures in community acquired pneumonia,” Journal of Chemotherapy, vol. 19, no. 5, pp. 536–545, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. P. R. Aguilar, K. Balsara, A. Itoh, and M. H. Kollef, “A noteworthy case of acute bronchitis,” Annals of the American Thoracic Society, vol. 13, no. 2, pp. 285–287, 2016. View at Google Scholar